CA-RSA
RSA Security LLC ("RSA" or the "Company") today announced the transition of its Fraud & Risk Intelligence business into a new standalone company serving a worldwide customer and partner community.
The new organization, Outseer, is led by CEO Reed Taussig who joined the RSA Fraud & Risk Intelligence business in late 2020 and is a veteran of the fraud prevention and digital identity industry.
With this strategic transition defined by self-directed company management and a modern corporate identity, Outseer will continue to deliver all heritage products in a newly constituted portfolio:
- Outseer Fraud Manager™: (formerly RSA Adaptive Authentication) protects customers across all digital channels with risk-based account monitoring decisions
- Outseer 3-D Secure™: (formerly RSA Adaptive Authentication for eCommerce) the gold standard in card-not-present and digital payments authentication mapping to the latest EMV® 3-D Secure standard
- Outseer FraudAction™: (formerly RSA FraudAction) delivers rapid detection, takedown, and data insights related to phishing sites, rogue apps, and fraudulent social media pages
Together, these award-winning offerings serve as the benchmark for payments authentication, detecting account compromise fraud, and fraud investigations while upholding friction-free customer experiences for the world’s leading merchants, issuing banks, and payment providers.
Underlying the Outseer product portfolio are two deep investments in data and science:
- Outseer Global Data Network™: The industry’s first global consortium of verified fraud and transaction data
- Outseer Risk Engine™: Identity-centric risk graph delivering 95% fraud detection rates with an intervention rate of 5% or less
“Outseer is the culmination of decades of science-driven innovation in anti-fraud and payments authentication solutions,” Taussig said. “As the digital economy continues to deepen, the Outseer mission to liberate the world from transactional fraud is essential. Our role as a revenue enabler for the global economy will only strengthen as every digital business continues to scale.”
This move follows the COVID-19 pandemic which fueled unprecedented growth in digital commerce, compressing a decade of transformation into 12 months. Payment card schemes, issuing banks, and commerce providers have witnessed unprecedented fraudulent transactions and even orchestrated attacks in their payment networks.
To meet these new challenges, Outseer will continue to innovate their payments authentication offerings, mapping closely to the EMV® 3-D Secure 2.x payment standard and incorporating new technology integrations across the payments and commerce ecosystem.
“Outseer’s reason for being isn’t just focused on eliminating payments and account fraud,” Taussig said. “These fraudulent transactions are often the pretext for more sinister drug and human trafficking, terrorism, and other nefarious behavior. Outseer has the ability to help make the world a safer place.”
Founded in 1982, RSA has built a reputation over four decades of being a critical solution provider for security-sensitive customers and a leader of innovation that enables enterprises to address rapidly evolving risks and security threats. Today, RSA services 2 billion individual users and has 26 million identities under management, and more than 12,500 customers rely on RSA's software solutions to enable their digital transformation, address increasingly advanced cyber threats and adapt to more complex digital regulations.
RSA announced in 2020 that it had begun operating as an independent company via acquisition by Symphony Technology Group, valuing the company at $2.1 billion.
Related resources:
- Watch the Outseer introduction video
- Visit Outseer.com
- Request a demo of Outseer products
About Outseer
Outseer, an RSA company, empowers the digital economy to grow by authenticating billions of transactions annually. Our payment and account monitoring solutions increase revenue and reduce customer friction for card issuing banks, payment processors, and merchants worldwide. Leveraging 20 billion annual transactions from 6,000 global institutions contributing to the Outseer Data Network, our identity-based science delivers the highest fraud detection rates and lowest customer intervention in the industry. See what others can’t at outseer.com .
About RSA
RSA, a leader in cybersecurity and risk management solutions, provides organizations with technology to address challenges across security, risk management and fraud prevention in the digital era. RSA solutions are designed to effectively detect and respond to advanced attacks; manage user access control; and reduce operational risk, fraud and cybercrime. RSA protects millions of users around the world and helps more than 90 percent of the Fortune 100 companies thrive and continuously adapt to transformational change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005320/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
